|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 November 1999 | Volume 131 Issue 9 | Pages 688-695
Atrial fibrillation is associated with a sixfold increased risk for stroke. More than a dozen published randomized trials of anticoagulants or antiplatelet agents for stroke prevention provide solid evidence on which to base antithrombotic prophylaxis. Adjusted-dose warfarin reduces risk for stroke by about 60% compared with placebo, aspirin reduces this risk (primarily for nondisabling stroke) by about 20% compared with placebo, and warfarin reduces it by about 40% compared with aspirin. Warfarin provides maximal protection against stroke at international normalized ratios of 2.0 to 3.0. Risk stratification of patients with atrial fibrillation identifies those who potentially benefit most or least from anticoagulation; this is important because a substantial percentage of patients with atrial fibrillation have relatively low rates of stroke if they are given aspirin. Many elderly patients with recurrent intermittent atrial fibrillation experience high rates of stroke and benefit from anticoagulation. The value of precordial or transesophageal echocardiography in addition to clinical risk stratifiers for stratifying stroke risk is controversial. Altered hemostasis favoring thrombosis may contribute to formation of atrial appendage thrombus, but these conditions remain ill defined.
The past decade has brought unprecedented progress toward understanding thromboembolism in patients with atrial fibrillation and has changed the clinical perspective of a prevalent cardiac arrhythmia into an important opportunity for stroke prevention. Making the most of this promise calls for appreciation of the epidemiology of atrial fibrillation and the concept of risk specificity in the face of diverse therapeutic options.
Author and Article Information
From University of Texas Health Sciences Center, San Antonio, Texas; and Mount Sinai Medical Center, New York, New York.
Note: Both authors were participants in the Stroke Prevention in Atrial Fibrillation I, II, and III clinical trials.
Requests for Reprints: Robert G. Hart, MD, Department of Medicine (Neurology), University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78284; e-mail, hartr{at}uthscsa.edu. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. Hart: Department of Medicine (Neurology), University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78284.
Dr. Halperin: The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029. UPDATE
Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention
![]()
This article has been cited by other articles:
![]() |
E. Z. Soliman, R. J. Prineas, L. D. Case, Z.-m. Zhang, and D. C. Goff Jr Ethnic Distribution of ECG Predictors of Atrial Fibrillation and Its Impact on Understanding the Ethnic Distribution of Ischemic Stroke in the Atherosclerosis Risk in Communities (ARIC) Study Stroke, April 1, 2009; 40(4): 1204 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Voeller, R. B. Schuessler, and R. J. Damiano Jr. Surgical Treatment of Atrial Fibrillation Card. Surg. Adult, January 1, 2008; 3(2008): 1375 - 1394. [Full Text] |
||||
![]() |
G. Tsivgoulis, S. Vassilopoulou, and K. Spengos Impact of Anticoagulation on Poststroke Mortality in Ischemic Stroke Patients With Atrial Fibrillation Stroke, July 1, 2007; 38(7): e61 - e61. [Full Text] [PDF] |
||||
![]() |
D. Dobre, D. J. van Veldhuisen, M. J.L. DeJongste, C. Lucas, G. Cleuren, R. Sanderman, A. V. Ranchor, and F. M. Haaijer-Ruskamp Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival Eur J Heart Fail, March 1, 2007; 9(3): 280 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Das, P. D. Willcoxson, O. J. Corrado, and R. M. West The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation Age Ageing, January 1, 2007; 36(1): 95 - 97. [Full Text] [PDF] |
||||
![]() |
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): 854 - 906. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): 700 - 752. [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Eur. Heart J., August 2, 2006; 27(16): 1979 - 2030. [Full Text] [PDF] |
||||
![]() |
A. Ahmed, J. Ness, G. Howard, and W. S. Aronow Cerebrovascular Diseases as Primary Hospital Discharge Diagnoses: National Trend (1970-2000) Among Older Adults J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2005; 60(10): 1328 - 1332. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Arima, R. G. Hart, S. Colman, J. Chalmers, C. Anderson, A. Rodgers, M. Woodward, S. MacMahon, B. Neal, and for the PROGRESS Collaborative Group Perindopril-Based Blood Pressure-Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack Stroke, October 1, 2005; 36(10): 2164 - 2169. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, A. V. Zima, F. Sheikh, L. A. Blatter, and J. Chen Endothelin-1-Induced Arrhythmogenic Ca2+ Signaling Is Abolished in Atrial Myocytes of Inositol-1,4,5-Trisphosphate(IP3)-Receptor Type 2-Deficient Mice Circ. Res., June 24, 2005; 96(12): 1274 - 1281. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Murphy Maximizing current treatment options: exploring psychological barriers to change Eur. Heart J. Suppl., June 1, 2005; 7(suppl_E): E10 - E14. [Full Text] [PDF] |
||||
![]() |
H.P. Kuhl and P. Hanrath The impact of transesophageal echocardiography on daily clinical practice Eur J Echocardiogr, December 1, 2004; 5(6): 455 - 468. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E Dager, T. G Vondracek, B. A McIntosh, and E. A Nutescu Ximelagatran: An Oral Direct Thrombin Inhibitor Ann. Pharmacother., November 1, 2004; 38(11): 1881 - 1897. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. Gage, C. van Walraven, L. Pearce, R. G. Hart, P. J. Koudstaal, B.S.P. Boode, and P. Petersen Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin Circulation, October 19, 2004; 110(16): 2287 - 2292. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Dager Ximelagatran: A New Antithrombotic Option in Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 151 - 162. [Abstract] [PDF] |
||||
![]() |
S. G. Rockson and G. W. Albers Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation J. Am. Coll. Cardiol., March 17, 2004; 43(6): 929 - 935. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Fang, R. S. Stafford, J. N. Ruskin, and D. E. Singer National Trends in Antiarrhythmic and Antithrombotic Medication Use in Atrial Fibrillation Arch Intern Med, January 12, 2004; 164(1): 55 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.J. Boos, J. Carlsson, and R.S. More Rate or rhythm control in persistent atrial fibrillation? QJM, December 1, 2003; 96(12): 881 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
Ph. Ricard, K. Yaici, J.P. Rinaldi, M. Bergonzi, and N. Saoudi Cardioversion of atrial fibrillation: how and when? Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H40 - H44. [Abstract] [PDF] |
||||
![]() |
T. J. Wang, J. M. Massaro, D. Levy, R. S. Vasan, P. A. Wolf, R. B. D'Agostino, M. G. Larson, W. B. Kannel, and E. J. Benjamin A Risk Score for Predicting Stroke or Death in Individuals With New-Onset Atrial Fibrillation in the Community: The Framingham Heart Study JAMA, August 27, 2003; 290(8): 1049 - 1056. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Wyse Rhythm management in atrial fibrillation: less is more J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1703 - 1706. [Full Text] [PDF] |
||||
![]() |
J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1633 - 1652. [Full Text] [PDF] |
||||
![]() |
J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy Circulation, April 1, 2003; 107(12): 1692 - 1711. [Full Text] [PDF] |
||||
![]() |
L. A Blatter, J. Kockskamper, K. A Sheehan, A. V Zima, J. Huser, and S. L Lipsius Local calcium gradients during excitation-contraction coupling and alternans in atrial myocytes J. Physiol., January 1, 2003; 546(1): 19 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Schafer, M. N. Levine, B. A. Konkle, and C. Kearon Thrombotic Disorders: Diagnosis and Treatment Hematology, January 1, 2003; 2003(1): 520 - 539. [Abstract] [Full Text] [PDF] |
||||
![]() |
The Atrial Fibrillation Follow-up Investigation of A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation N. Engl. J. Med., December 5, 2002; 347(23): 1825 - 1833. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Van Gelder, V. E. Hagens, H. A. Bosker, J. H. Kingma, O. Kamp, T. Kingma, S. A. Said, J. I. Darmanata, A. J.M. Timmermans, J. G.P. Tijssen, et al. A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation N. Engl. J. Med., December 5, 2002; 347(23): 1834 - 1840. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Garcia, F. Marin, B. Sanchez, V. Roldan, P. Marco, G.Y.H. Lip, K.H. Tan, C. Lau, and E. Williams Diurnal Variation in the Intensity of Anticoagulation in Atrial Fibrillation Stroke, January 1, 2002; 33(1): 322 - 324. [Full Text] [PDF] |
||||
![]() |
A. Evans, I. Perez, G. Yu, and L. Kalra Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients With Atrial Fibrillation? Stroke, December 1, 2001; 32(12): 2828 - 2832. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology Circulation, October 23, 2001; 104(17): 2118 - 2150. [Full Text] [PDF] |
||||
![]() |
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923. [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1231 - 1265. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266. [Full Text] [PDF] |
||||
![]() |
M. Copland, I. D. Walker, and R. C. Tait Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population With Atrial Fibrillation Arch Intern Med, September 24, 2001; 161(17): 2125 - 2128. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Evans and L. Kalra Are the Results of Randomized Controlled Trials on Anticoagulation in Patients With Atrial Fibrillation Generalizable to Clinical Practice? Arch Intern Med, June 11, 2001; 161(11): 1443 - 1447. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Hart and J. L. Halperin Atrial Fibrillation and Stroke : Concepts and Controversies Stroke, March 1, 2001; 32(3): 803 - 808. [Full Text] [PDF] |
||||
![]() |
N. Cohen, D. Almoznino-Sarafian, I. Alon, O. Gorelik, M. Koopfer, S. Chachashvily, M. Shteinshnaider, V. Litvinjuk, and D. Modai Warfarin for Stroke Prevention Still Underused in Atrial Fibrillation : Patterns of Omission Stroke, June 1, 2000; 31(6): 1217 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J Ellis, R. Hans, J. Mant, D. Fitzmaurice, E. Murray, R. Hobbs, A. Evans, I. Perez, L. Kalra, F. H Rutten, et al. Using anticoagulation or aspirin to prevent stroke BMJ, April 8, 2000; 320(7240): 1008 - 1008. [Full Text] |
||||
![]() |
B. N. Singh and S. Doshi Maintaining Sinus Rhythm in Atrial Fibrillation by Drug Therapy: Single Agents or Combinations? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 139 - 142. [PDF] |
||||